Loading stock data…
Generate Biomedicines, Inc. (GENB)
$15.90-0.49 (-2.99%)
Market ClosedLast close Sep 8
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $7.22M↓ | $8.82M |
| Gross Profit | — | — |
| Operating Income | -$64.11M↓ | -$48.15M |
| Net Income | -$61.45M↓ | -$41.69M |
Peer Comparison
JNJUNHPFE
Fundamentals
Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.65B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-20.03%
Volume
Today's trading volume
1.26M
Recent News
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
Arm Holdings PLC CEO Rene Haas said artificial intelligence could help find a cure for cancer within our lifetime, but warned that chip shortages are limiting the expansion of AI infrastructure. Haas said AI could eventually solve complex problems in...
How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
Nvidia has big investments in Intel, SpaceX and many more public companies. But its stakes in OpenAI and Anthropic are the real prize.
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
Moderna’s upsized note offering quickly followed a big win in a crucial study. Elsewhere, a biotech’s shares tumbled after study data were “inadvertently” published ahead of a medical meeting.
EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
Nvidia Corp‘s GPUs have become the backbone of artificial intelligence, but they won’t be enough to determine the winners in AI-driven drug discovery. In an exclusive email interview with Benzinga, Generate Biomedicines co-founder and CTO Gevorg Grigoryan said advanced computing...
Cathie Wood Sends a $20 Million Signal on Broadcom Stock
Cathie Wood Makes a Bold AI Chip Rotation From AMD to Broadcom